At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 31 enrolled
Drug / intervention
Influenza Virus Vaccine (Fluzone®) +1 morebiological
Likely dose
Influenza Virus Vaccine (Fluzone®) 0.25 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Annual Study for Serum Collection and Evaluation of Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2006-2007 Formulation)
In Brief
A Phase 4 clinical trial evaluating Influenza Virus Vaccine (Fluzone®) for Influenza. Completed, enrolled 31 participants across 1 site.
Detailed Summary
To provide Centers for Biologics Evaluation and Research (CBER) with sera collected from healthy children receiving the 2006-2007 formulation of the inactivated, split-virion influenza vaccine Fluzone® for further study by the Food and Drug Administration (FDA), Center for Disease Control and Prevention (CDC) and World Health Organization (WHO).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedOct 2006
Primary CompletionSep 2007
Study CompletionJul 2008
TodayJul 2026
First PostedOct 19, 2006
Enrollment StartOct 1, 2006
Primary CompletionSep 1, 2007
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.7 years ago
Interventions
Influenza Virus Vaccine (Fluzone®)biological
0.25 mL, Intramuscular (infant/children dose)
Influenza Virus Vaccine (Fluzone®)biological
0.25 mL, Intramuscular (infant/children dose)